Stock DNA
Pharmaceuticals & Biotechnology
USD 21,770 Million (Mid Cap)
22.00
NA
0.00%
0.61
-999,999.00%
2.53
Revenue and Profits:
Net Sales:
3,538 Million
(Quarterly Results - Mar 2026)
Net Profit:
278 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.06%
0%
21.06%
6 Months
17.23%
0%
17.23%
1 Year
19.99%
0%
19.99%
2 Years
48.99%
0%
48.99%
3 Years
46.4%
0%
46.4%
4 Years
44.93%
0%
44.93%
5 Years
29.16%
0%
29.16%
Labcorp Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.04%
EBIT Growth (5y)
-12.50%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
27.54%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
2.53
EV to EBIT
17.82
EV to EBITDA
12.30
EV to Capital Employed
1.95
EV to Sales
1.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.93%
ROE (Latest)
11.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 138 Schemes (43.71%)
Foreign Institutions
Held by 356 Foreign Institutions (18.8%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
3,537.60
3,515.80
0.62%
Operating Profit (PBDIT) excl Other Income
560.50
555.00
0.99%
Interest
55.10
55.00
0.18%
Exceptional Items
-6.40
-114.40
94.41%
Consolidate Net Profit
278.00
164.90
68.59%
Operating Profit Margin (Excl OI)
109.50%
108.70%
0.08%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.62% vs -1.34% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 68.59% vs -36.94% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
13,951.70
13,008.90
7.25%
Operating Profit (PBDIT) excl Other Income
2,477.30
2,037.90
21.56%
Interest
224.10
208.30
7.59%
Exceptional Items
-142.60
-51.30
-177.97%
Consolidate Net Profit
877.70
747.10
17.48%
Operating Profit Margin (Excl OI)
108.70%
87.50%
2.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.25% vs 6.97% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 17.48% vs 96.40% in Dec 2024






